Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | GPX4 | P36969 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19353418 | 0.89 | BTK (0.42) | BTKEPHX2GPX4KMT2APDE4B | |
| SCHEMBL19353422 | 0.89 | BTK (0.42) | BTKEPHX2GPX4KMT2APDE4B | |
| SCHEMBL19353417 | 0.89 | BTK (0.42) | BTKEPHX2GPX4KMT2APDE4B | |
| SCHEMBL19352909 | 0.86 | GNAI3 (0.40) | BTKGPX4KMT2APDE4BMEN1 | |
| SCHEMBL20892778 | 0.80 | BTK (0.41) | BTKGPX4KMT2APDE4BMEN1 | |
| SCHEMBL24244433 | 0.80 | BTK (0.41) | BTKEPHX2KMT2APDE4BMEN1 | |
| SCHEMBL20371370 | 0.80 | BTK (0.41) | BTKEPHX2KMT2APDE4BMEN1 | |
| SCHEMBL16907738 | 0.79 | ALDH1A1 (0.47) | BTKGPX4KMT2APDE4BMEN1 | |
| SCHEMBL20144240 | 0.78 | GPX4 (0.41) | BTKEPHX2GPX4KMT2APDE4B | |
| SCHEMBL12840905 | 0.77 | GPX4 (0.40) | BTKGPX4KMT2APDE4BMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426637-B1 | COMPOUNDS AND METHODS FOR MODULATING BRUTON'S TYROSINE KINASE | ANGEL PHARMACEUTICAL CO LTD (CN) | 2022-02-09 | — | — | EP | disclosed |
| US-10005782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BEIGENE, LTD. (KY) | 2018-06-26 | — | — | US | disclosed |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005782-B2 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | BTK, LCK, SYK | BTK 1/4885EPHX2 2768/4885GPX4 3591/4885 |
| US-20160083392-A1 | Fused heterocyclic compounds as protein kinase inhibitors | BTK, WEE1, LYN | BTK 1/4885EPHX2 2437/4885GPX4 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.